Evogliptin

Evogliptin

Evogliptin

Chemical compound

Evogliptin (INN; trade names Suganon, Evodine) is an antidiabetic drug in the dipeptidyl peptidase-4 (DPP-4) inhibitor or "gliptin" class of drugs.[1] It was developed by the South Korean pharmaceutical company Dong-A ST and is approved for use in South Korea[2] and Russia.[3] In a meta-analysis involving data from 6 randomized controlled trials (887 patients), Dutta et. al. demonstrated the good glycaemic efficacy and safety of this medicine as compared to other DPP4 inhibitors like sitagliptin and linagliptin. [4]

Quick Facts Clinical data, Trade names ...

References

  1. [1]
    McCormack PL (November 2015). "Evogliptin: First Global Approval". Drugs. 75 (17): 2045–9. doi:10.1007/s40265-015-0496-5. PMID 26541763. S2CID 46450821.
  2. [2]
    "Dong-A ST's DPP4 inhibitor, SUGANON, got approved for type 2 diabetes in Korea". pipelinereview.com. October 2, 2015. Archived from the original on June 30, 2022. Retrieved February 1, 2017.
  3. [3]
    "Evodine (evogliptin) film-coated tablets. Full prescribing information". Russian State Register of Medicines (in Russian).
  4. [4]
    Dutta D, Bhattacharya S, Krishnamurthy A, Sharma LK, Sharma M (Nov 2020). "Efficacy and Safety of Novel Dipeptidyl-Peptidase-4 Inhibitor Evogliptin in the Management of Type 2 Diabetes Mellitus: A Meta-Analysis". Indian J Endocrinol Metab. 24 (5): 434–445. doi:10.4103/ijem.IJEM_418_20. PMC 7810058. PMID 33489850.
Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Evogliptin, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.